Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

In today's Asking Eric column, R. Eric Thomas responds to someone who is disappointed their friends didn't notice their ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

Now, after gaining all that weight back due to not being able to continually and severely restrict my diet, I am using ...

The Dalai Lama said on Wednesday the institution of the Dalai Lama will continue and the Gaden Phodrang trust has sole ...

Dear Eric: Regarding your response to “What to Say”, who didn’t know how to address a friend’s Ozempic weight loss: ...

A Delhi HC directive to examine unregulated use of weight loss drugs may lead to a CDSCO expert panel by mid-July, possibly ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

The drug is now available for prescription in New Zealand but there are clouds to go along with the silver linings - such as ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

As weight-loss drugs like semaglutide and tirzepatide dominate global headlines, a new nationwide survey shows that 87 per cent of Indian adults beli ...